These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

277 related items for PubMed ID: 35862646

  • 1. Prospective study of Na[18F]F PET/CT for cancer staging in morbidly obese patients compared with [99mTc]Tc-MDP whole-body planar, SPECT and SPECT/CT.
    Usmani S, Ahmed N, Gnanasegaran G, Al Kandari F, Marafi F, Bani-Mustafa A, Musbah A, Jassem Almashmoum M, Van den Wyngaert T.
    Acta Oncol; 2022 Oct; 61(10):1230-1239. PubMed ID: 35862646
    [Abstract] [Full Text] [Related]

  • 2. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer.
    Qiu ZL, Xue YL, Song HJ, Luo QY.
    Nucl Med Commun; 2012 Dec; 33(12):1232-42. PubMed ID: 23111353
    [Abstract] [Full Text] [Related]

  • 3. Prospective study evaluating the relative sensitivity of 18F-NaF PET/CT for detecting skeletal metastases from renal cell carcinoma in comparison to multidetector CT and 99mTc-MDP bone scintigraphy, using an adaptive trial design.
    Gerety EL, Lawrence EM, Wason J, Yan H, Hilborne S, Buscombe J, Cheow HK, Shaw AS, Bird N, Fife K, Heard S, Lomas DJ, Matakidou A, Soloviev D, Eisen T, Gallagher FA.
    Ann Oncol; 2015 Oct; 26(10):2113-8. PubMed ID: 26202597
    [Abstract] [Full Text] [Related]

  • 4. Intra-individual comparison of 18F-sodium fluoride PET-CT and 99mTc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer at high risk for skeletal metastases (MITNEC-A1): a multicentre, phase 3 trial.
    Bénard F, Harsini S, Wilson D, Zukotynski K, Abikhzer G, Turcotte E, Cossette M, Metser U, Romsa J, Martin M, Mar C, Saad F, Soucy JP, Eigl BJ, Black P, Krauze A, Burrell S, Nichol A, Tardif JC.
    Lancet Oncol; 2022 Dec; 23(12):1499-1507. PubMed ID: 36343655
    [Abstract] [Full Text] [Related]

  • 5. A Prospective Study Comparing 99mTc-Hydroxyethylene-Diphosphonate Planar Bone Scintigraphy and Whole-Body SPECT/CT with 18F-Fluoride PET/CT and 18F-Fluoride PET/MRI for Diagnosing Bone Metastases.
    Löfgren J, Mortensen J, Rasmussen SH, Madsen C, Loft A, Hansen AE, Oturai P, Jensen KE, Mørk ML, Reichkendler M, Højgaard L, Fischer BM.
    J Nucl Med; 2017 Nov; 58(11):1778-1785. PubMed ID: 28798033
    [Abstract] [Full Text] [Related]

  • 6. Comparison of Bone Metastases between 18F-NaF PET/CT, 18F-NaF PET, and Planar 99mTc-MDP Bone Scintigraphy in Patients with Newly Diagnosed Nasopharyngeal Carcinoma.
    Wang D, Yang Y, Zeng Z, Ye J, Guo C, Huang S, Guo X, Xiao J.
    Contrast Media Mol Imaging; 2022 Nov; 2022():5975338. PubMed ID: 35494210
    [Abstract] [Full Text] [Related]

  • 7. Prospective evaluation of (99m)Tc MDP scintigraphy, (18)F NaF PET/CT, and (18)F FDG PET/CT for detection of skeletal metastases.
    Iagaru A, Mittra E, Dick DW, Gambhir SS.
    Mol Imaging Biol; 2012 Apr; 14(2):252-9. PubMed ID: 21479710
    [Abstract] [Full Text] [Related]

  • 8. Accurate characterization of 99mTc-MDP uptake in extraosseous neoplasm mimicking bone metastasis on whole-body bone scan: contribution of SPECT/CT.
    Zhang L, He Q, Zhou T, Zhang B, Li W, Peng H, Zhong X, Ma L, Zhang R.
    BMC Med Imaging; 2019 May 30; 19(1):44. PubMed ID: 31146746
    [Abstract] [Full Text] [Related]

  • 9. Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial.
    Jambor I, Kuisma A, Ramadan S, Huovinen R, Sandell M, Kajander S, Kemppainen J, Kauppila E, Auren J, Merisaari H, Saunavaara J, Noponen T, Minn H, Aronen HJ, Seppänen M.
    Acta Oncol; 2016 May 30; 55(1):59-67. PubMed ID: 25833330
    [Abstract] [Full Text] [Related]

  • 10. Comparison of 18F fluoride PET/CT and 99mTc-MDP bone scan in the detection of skeletal metastases in urinary bladder carcinoma.
    Chakraborty D, Bhattacharya A, Mete UK, Mittal BR.
    Clin Nucl Med; 2013 Aug 30; 38(8):616-21. PubMed ID: 23603596
    [Abstract] [Full Text] [Related]

  • 11. Comparison of diagnostic ability between (99m)Tc-MDP bone scan and (18)F-FDG PET/CT for bone metastasis in patients with small cell lung cancer.
    Lee JW, Lee SM, Lee HS, Kim YH, Bae WK.
    Ann Nucl Med; 2012 Oct 30; 26(8):627-33. PubMed ID: 22729551
    [Abstract] [Full Text] [Related]

  • 12. What Is the Comparative Ability of 18F-FDG PET/CT, 99mTc-MDP Skeletal Scintigraphy, and Whole-body MRI as a Staging Investigation to Detect Skeletal Metastases in Patients with Osteosarcoma and Ewing Sarcoma?
    Aryal A, Kumar VS, Shamim SA, Gamanagatti S, Khan SA.
    Clin Orthop Relat Res; 2021 Aug 01; 479(8):1768-1779. PubMed ID: 33635285
    [Abstract] [Full Text] [Related]

  • 13. Quantitative 99mTc-MDP SPECT/CT as an alternative to 18F-NaF PET/CT for objective assessment of osteoblastic bone metastases.
    Coskun N, Cagdas B, Yildirim N.
    Hell J Nucl Med; 2022 Aug 01; 25(2):132-137. PubMed ID: 35913859
    [Abstract] [Full Text] [Related]

  • 14. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019 Aug 01; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 15. Spine metastases in prostate cancer: comparison of technetium-99m-MDP whole-body bone scintigraphy, [(18) F]choline positron emission tomography(PET)/computed tomography (CT) and [(18) F]NaF PET/CT.
    Poulsen MH, Petersen H, Høilund-Carlsen PF, Jakobsen JS, Gerke O, Karstoft J, Steffansen SI, Walter S.
    BJU Int; 2014 Dec 01; 114(6):818-23. PubMed ID: 24314065
    [Abstract] [Full Text] [Related]

  • 16. Head-to-head comparison of 99mTc-PSMA and 99mTc-MDP SPECT/CT in diagnosing prostate cancer bone metastasis: a prospective, comparative imaging trial.
    Zhang Y, Lin Z, Li T, Wei Y, Yu M, Ye L, Cai Y, Yang S, Zhang Y, Shi Y, Chen W.
    Sci Rep; 2022 Sep 26; 12(1):15993. PubMed ID: 36163353
    [Abstract] [Full Text] [Related]

  • 17. The diagnostic and prognostic effectiveness of F-18 sodium fluoride PET-CT in detecting bone metastases for hepatocellular carcinoma patients.
    Yen RF, Chen CY, Cheng MF, Wu YW, Shiau YC, Wu K, Hong RL, Yu CJ, Wang KL, Yang RS.
    Nucl Med Commun; 2010 Jul 26; 31(7):637-45. PubMed ID: 20389259
    [Abstract] [Full Text] [Related]

  • 18. Prospective comparison of whole-body bone SPECT and sodium 18F-fluoride PET in the detection of bone metastases from breast cancer.
    Abikhzer G, Srour S, Fried G, Drumea K, Kozlener E, Frenkel A, Israel O, Fogelman I, Kagna O.
    Nucl Med Commun; 2016 Nov 26; 37(11):1160-8. PubMed ID: 27536906
    [Abstract] [Full Text] [Related]

  • 19. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT.
    Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I.
    J Nucl Med; 2006 Feb 26; 47(2):287-97. PubMed ID: 16455635
    [Abstract] [Full Text] [Related]

  • 20. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer.
    Minamimoto R, Loening A, Jamali M, Barkhodari A, Mosci C, Jackson T, Obara P, Taviani V, Gambhir SS, Vasanawala S, Iagaru A.
    J Nucl Med; 2015 Dec 26; 56(12):1862-8. PubMed ID: 26405167
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.